Tradestie Institutional Equity Comparison Engine

LQDA vs ZBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LQDA Overall Edge

LQDA Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Liquidia Corporation Common Stock (LQDA) driven by superior Valuation, Growth & Margin, Momentum & Technical while ZBIO counters with relative strength in Options & Structure. Fundamentally, LQDA trades at 16.4x Forward P/E with 47.1% operating margin (+314.6% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, LQDA sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LQDA
LQDA 16.4x vs ZBIO N/M Fwd P/E
Growth & Margin Winner LQDA
Op Margin 47.1% vs -2747.5% ยท YoY +314.6% vs -100.0%
Momentum & Technical Winner LQDA
1Y +109.2% vs -21.7% ยท 52W Pos 48% vs 46%
Options & Structure Winner ZBIO
BREAKDOWN (10th %ile IV) vs CONSOLIDATION (13th %ile IV)
LQDA NASDAQ
Liquidia Corporation Common Stock
Pharmaceutical Preparations
$56.37
-1.81% 1D
Market Cap $5.2B
1M Return +64.1%
1Y Return +109.24%
Forward P/E 16.4x
Unified AI Score
25.6 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LQDA +109.24% ZBIO -21.68% Spread: +130.92 pp (LQDA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LQDA Revenue ZBIO Revenue LQDA Op. Margin ZBIO Op. Margin Margin Edge
FY2019 $10M N/A -580.1% N/A LQDA
FY2020 $0M N/A -7989.0% N/A LQDA
FY2021 $10M N/A -263.0% N/A LQDA
FY2022 $20M N/A -243.3% N/A LQDA
FY2023 $20M $50M -419.6% -74.3% ZBIO
FY2024 $10M $10M -866.6% -3277.8% LQDA
FY2025 $160M $10M -32.5% -3830.6% LQDA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LQDA (7) vs ZBIO (3)
Institutional Metric LQDA ZBIO Criterion Row Winner
Market Capitalization Scale $5.2B $1.9B Larger Scale LQDA
Trailing P/E Ratio Valuation 13.8x N/M Lower Multiple LQDA
Forward P/E Ratio Valuation 16.4x N/M Lower Multiple LQDA
Revenue Growth (YoY) Growth +314.6% -100.0% Higher Growth LQDA
Operating Margin (TTM) Profitability 47.1% -2747.5% Higher Margin LQDA
Net Profit Margin Profitability -15.2% 0.0% Higher Margin ZBIO
Return on Equity (ROE) Capital Efficiency 131.8% -265.1% Higher ROE LQDA
52-Week Range Position Momentum 48% ($22โ€“$94) 46% ($14โ€“$45) Stronger Trend LQDA
Beta / 30D Volatility Risk Regime 0.99ฮฒ ยท 77% Vol 1.16ฮฒ ยท 59% Vol Lower Realized Risk ZBIO
Unified Institutional Score Composite Signal 25.6 / 100 (SELL) 49.4 / 100 (HOLD) Higher Composite ZBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LQDA vs ZBIO Buy Guide
LQDA BREAKDOWN
81d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live LQDA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LQDA nor ZBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.